Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study
Pau Montesinos, MD discusses key updates from the global phase 3 AGILE study, as presented at the 2022 American Society of Hematology Annual Meeting, and speaks to the clinical implications of these data.
Related Videos
Related Content
